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Abstract
Background: Epigenetic silencing of tumor suppressor genes associated with promoter methylation is
considered to be a hallmark of oncogenesis. RASSF1A is a candidate tumor suppressor gene which was
found to be inactivated in many human cancers. Although we have had a prelimilary cognition about the
function of RASSF1A, the exact mechanisms about how RASSF1A functions in human cancers were largely
unknown. Moreover, the effect of mutated K-Ras gene on the function of RASSF1A is lacking. The aim of
this study was to investigate the expression profile and methylation status of RASSF1A gene, and to
explore its concrete mechanisms as a tumor suppressor gene in Nasopharyngeal Carcinoma.
Methods: We examined the expression profile and methylation status of RASSF1A in two NPC cell lines,
38 primary nasopharyngeal carcinoma and 14 normal nasopharyngeal epithelia using RT-PCR and
methylated specific PCR(MSP) respectively. 5-aza-dC was then added to confirm the correlation between
hypermethylation status and inactivation of RASSF1A. The NPC cell line CNE-2 was transfected with
exogenous pcDNA3.1(+)/RASSF1A plasmid in the presence or absence of mutated K-Ras by liposome-
mediated gene transfer method. Flow cytometry was used to examine the effect of RASSF1A on cell cycle
modulation and apoptosis. Meanwhile, trypan blue dye exclusion assays was used to detect the effect of
RASSF1A transfection alone and the co-transfection of RASSF1A and K-Ras on cell proliferation.
Results: Promoter methylation of RASSF1A could be detected in 71.05% (27/38) of NPC samples, but
not in normal nasopharyngeal epithelia. RASSF1A expression in NPC primary tumors was lower than that
in normal nasopharyngeal epithelial (p < 0.01). Expression of RASSF1A was down-regulated in two NPC
cell lines. Loss of RASSF1A expression was greatly restored by the methyltransferase inhibitor 5-aza-dC
in CNE-2. Ectopic expression of RASSF1A in CNE-2 could increase the percentage of G0/G1 phase cells
(p < 0.01), inhibit cell proliferation and induce apoptosis (p < 0.001). Moreover, activated K-Ras could
enhance the growth inhibition effect induced by RASSF1A in CNE-2 cells (p < 0.01).
Conclusion:  Expression of RASSF1A is down-regulated in NPC due to the hypermethylation of
promoter. Exogenous expression of RASSF1A is able to induce growth inhibition effect and apoptosis in
tumor cell lines, and this effect could be enhanced by activated K-Ras.
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Background
Nasopharyngeal carcinoma (NPC) is a serious and com-
mon cancer in Southern China. The tumorigenesis of NPC
is a multistage process involving cellular genetic predispo-
sition, epigenetic alterations, including the influence of
environment factors, diet and Epstein-Barr virus (EBV)
infection[1,2]. However, the molecular basis leading to
the development and spread of NPC remain largely
unknown. Recent years, several studies [3,4] showed that
silence of tumor suppressor genes by epigenetic modifica-
tion is a major mechanism for inactivation of cancer-
related genes in the pathogenesis of human cancers.
Cheng et al. reported that epigenetic events, including
DNA methylation and chromatin structure changes, are
among the earliest molecular alterations during malig-
nant transformation of human mammary epithelial
cells[5]. Methylation of the CpG islands of DNA promoter
is the most important and common epigenetic mecha-
nism leading to gene silence[6]. Consequently, identifica-
tion of genes targeted by hypermethylation may provide
insight into NPC tumorigenesis.
A numer of tumor suppressor genes have been implicated
to harbor promoter methylation at CpG islands in NPC,
such as RASSF1A (Ras association domain family 1 iso-
form A), p16, BLU [7,8] and recently LARS2 (leucyl-tRNA
synthetase 2, mitochondrial) was found to involve in this
process[9]. RASSF1A inactivation is essential for tumor
development. Moreover, there is growing evidence dem-
onstrating that a high frequency of methylation associated
inactivation of the tumor suppressor gene RASSF1A was
detected in a wide range of human cancers [10-13].
Since methylation of the RASSF1A promoter is described
as an early and frequent event in tumorigenesis, it could
serve as a useful diagnostic signal in cancer screens. Previ-
ous studies suggested that RASSF1A may implicate in var-
ious cellular mechanisms including cell cycle arrest,
apoptosis, inhibition of cell proliferation in vitro [14-17]
as well as repression of tumor formation in nude mice
[18], however, little is known about the underlying mech-
anisms of RASSF1A. The most interesting structure feature
of RASSF1A proteins is the presence of a Ras association
(RA) domain, which determines the role of RASSF1A pro-
tein functions as a Ras-effector, and endows RASSF1A the
ability to interact with Ras family protein[18]. The Ras
proteins are intimately involved in the regulation of a
wide variety of biological processes by interacting with
different downstream effectors. Although it is widely
accepted that the Ras functions as an oncoprotein that
contribute to cell proliferation through the RAS-MAP-
kinase pathway and antiapoptotic effect, more and more
studies found that it also induces growth arrest of cells,
such as apoptosis and senescence by interact with specific
effectors [19]. RASSF1A, act as a newly discovered down-
stream negative effector of Ras protein, may interact with
Ras protein in a GTP-dependent manner and induce a
potent, Ras-mediated apoptosis [20].
In this study, we characterized the hypermethylation sta-
tus of promoter of RASSF1A in NPC tumor biopsies and
normal nasopharyngeal epithelia. Growth inhibition
effect including cell cycle arrest, apoptosis and senescence
was also observed in CNE-2 cells that were transfected
with exogenous RASSF1A gene. Furthermore, we have ini-
tiated to figure out whether this tumor suppression effect
of RASSF1A could be enhanced in the presence of acti-
vated Ras.
Materials and methods
NPC cell lines and tissue samples
Two NPC cell lines, CNE1 and CNE2 were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum at
37°C. A total of 38 primary tumor biopsies cases were
obtained from newly diagnosed and untreated NPC
patients with consent and 14 samples of normal nasopha-
ryngeal epithelial tissues were obtained from the sus-
pected patients as normal controls at the department of
otolaryngology at the Union Hospital of Tongji Medical
College (Wuhan, China). All of the specimens were sub-
jected to histological diagnosis by pathologists according
to the WHO classification. Relative data involving age,
gender, clinical stage, lymph node metastasis and distance
metastasis were collected after the patients visiting. High-
molecular weight DNA was extracted from the samples
using DNA extract kit (Tiangen) according to the manu-
facture's instructions.
RT-PCR
Total RNAs from cell lines, normal nasopharyngeal epi-
thelia and tumor biopsies was isolated with TriZOL regent
(Huashun biotechnology). One micrograms of total RNA
was used for the first strand synthesis of cDNA by ReverTra
Ace™ Kit (TOYOBO, Janpan). The PCR was carried out in
a total volume of 25 μl PCR reaction containing 10 pmol
of each primer, 2.5 μl of deoxy-ribonucleoside triphos-
phate, 1 × PCR buffer, 1 unit of Taq polymerase (Ferman-
tas) and 2 μl of template cDNA. The primer sequences
used for amplification of RASSF1A were 5'-CTTTTACCT-
GCCCAAGGA TGC-3' and 5'-CACCTCCCCAGAGT-
CATTTTC-3'. The primers for GAPDH (5'-
CATGACAACTTTGGTATCGTG-3' and 5'-GTGTCGCT-
GTTGAAGTCGTCAG A-3') were used as internal control,
and the annealing temperature was 55°C for RASSF1A
and 58°C for GAPDH. After 25 cycles, 8 μl of PCR prod-
ucts were loaded onto a 1.5% agarose gels, stained with
GoldView, and visualized under UV illumination.
Sodium bisulfite modification
High-molecular weight genomic DNA from primary
tumor biopsies and normal nasopharyngeal epithelial tis-
sues were subjected to bisulfite modification by using theJournal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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CpGenome™ DNA Modification Kit (Chemicon Interna-
tional, USA) according to the manufacture's instruction;
Treatment of genomic DNA with sodium bisulfite con-
verts unmethylated cytosines, but not methylated
cytosines to uracil, which is then converted to thymidine
during the subsequent methylated specific PCR steps [21].
Methylated specific PCR
The methylation status of RASSF1A promoter region was
detected by methylated-specific PCR assay, PCR primers
that distinguishing unmethylated (U) and methylated
(M) DNA sequences were described by Burbee et al.[22].
The primers used to detect the methylated form were 5'-
GGGTTTTGCGAGAGCGCG-3'(forward) and 5'-
GCTAACAAACGCGAACCG-3'(reverse), and the primers
to detect the unmethylated form were 5'-GGTTTTGTGA-
GAGTGTGTTTAG-3' (forward) and 5'-
CACTAACAAACACAAACCAAAC-3' (reverse). Each
primer set generated a 169-bp product. Genomic DNAs,
modified by bisulfite treatment, were used as a template
for methylated specific PCR (MSP). Each MSP reaction
incorporated 2 μl of sodium bisulfite-modified DNA, 10
pmol of each primer, 2.5 μl of deoxy-ribonucleoside tri-
phosphate, 1 × PCR buffer, MgCl2  and 1 unit Taq
polymerase (Fermantas) in a final PCR reaction volume of
25 μl. The annealing temperature was 64°C for methyla-
tion-specific and 59°C for unmethylation-specific prim-
ers. DNA modified by methylase Sss I was used as a
positive control and water was included as negative con-
trol. The PCR products were separated on 2% agarose gels
stained with GoldView fluorochrome (Saibaisheng) and
visualized under UV illumination.
5-Aza-2'-deoxycytidine treatment
To determine whether RASSF1A expression could be
restored by the demethylating agents, the NPC cell line
CNE-2, which showed to have lower expression of
RASSF1A than CNE-1 in our studies, was subjected to 5-
aza-2'-deoxycytidine treatment. 2 × 105 CNE-2 cells were
plated in a six-well plate and incubated for 4 d with 0, 1,
3, 5, 7, 10 μmol/L 5-aza-2'-deoxycytidine (Sigma). The
medium and drug were replaced every 24 h. The re-expres-
sion and alteration of methylation status of RASSF1A in
NPC cell line CNE-2 after 5-aza-dC treatment was exam-
ined by RT-PCR and MSP as described previously in our
study.
Plasmids and transfection
Growth inhibition assays were performed by transiently
transfecting CNE-2 cells with 3 μg of pcDNA3.1(+)/
RASSF1A construct (a generous gift from Prof. Reinhard
Dammann, Department of Biology, Beckman Research
Institute, City of Hope Medical Center, Duarte, California,
USA.) or pcDNA3.1(+) empty vector using Lipofectamine
2000 (Invitrogen, USA). pCGN-HA-RasG12V (a generous
gift from Prof. Geoffrey J. Clark, Department of Cell and
Cancer Biology, National Cancer Institute, Rockville, Mar-
yland, USA.), which contains the cDNAs encoding acti-
vated K-Ras gene, was used to perform co-transfection
with pcDNA3.1(+)/RASSF1A in CNE-2 cells. Transfection
was performed using Lipofectamine 2000 (Invitrogen,
USA) according to the manufacturer's instruction. The
expression of exogenous RASSF1A and K-RasG12V was
confirmed by RT-PCR analysis and western-bloting.
Western-blot analysis
Cells were grown and harvested at 70-80% confluency,
cellular protein were extracted with lysis buffer which con-
tains PMSF, a protease inhibitors (BOSTER), Lysates were
incubated on ice for 30 min, and insoluble cell debris was
removed by centrifugation for 10 min at 12,000 rpm at
4°C. Protein samples were separated by 10-15% SDS-
PAGE and were electroblotted to PVDF membranes
(Roche) and stained with enhanced chemiluminescence
solution. For detection of bound primary antibody, the
membranes were then incubated with the mouse mono-
clonal anti-RASSF1A (eBioscience). β-actin protein level
were used as a control for equal protein loading.
Cell death assay
CNE-2 cell death assays were performed by transfection
cells with 4 μg each of empty vector or pcDNA3.1 (+)
RASSF1A in the presence or absence of 40 ng of K-Ras12V.
Briefly, 1.5 × 105 CNE-2 cells were seeded in 6-well plates
one day before transfection, 48 h post-transfection, trypan
blue was added in situ at a final concentration of 0.04%.
Dead cells were quantitated by counting the number of
blue cells in three random 40 × field using phase/contrast
microscopy.
Cell cycle analysis
Cell cycle analysis was performed in CNE-2 cells after the
treatment of 5-aza-dC for 4 d and transfected with 3 μg of
pcDNA3.1 (+)/RASSF1A or empty vector using Lipo-
fectamine 2000. Four days after agent treatment and 48 h
after transfection, cells were harvested and fixed in ice-
cold 70% ethanol at 4°C overnight. Then cells were
washed twice with ice-cold PBS and pelleted by centrifu-
gation and the ethanol was decanted. Cells were resus-
pended at a concentration of 1 × 106 cells/ml in staining
solution (65 μg/ml propidium iodide, 50 μg/ml RNase
A). After incubation at 37°C in dark for 30 min, cells were
subjected to flow cytometry (FACSort) analysis. Cellular
DNA content was assessed and cell cycle model was
acquired.
Apoptosis assays
CNE-2 cells were transfected with 4 μg of RASSF1A in the
presence or absence of 40 ng of K-RasG12V or empty vec-
tor using Lipofectamine 2000. Annexin-V binding wasJournal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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used to measure apoptosis. 1 × 105 cells were seeded in 6-
well dishes. 48 h post-transfection, cells were harvested
using trypsin, washed with ice-cold PBS, resuspended in
500 μl annexin-V binding buffer and incubated at room
temperature with 5 μl of each of Annexin-V and Propid-
ium Iodide (Annexin V-FITC apoptosis detection kit; Nan-
Jing KeyGen Biotech. Co. LTD) for 15 min in dark. Then,
a FACSort flow cytometer was used to measure Annexin-
V-PI binding.
Statistical analysis
Statistical analysis was performed by software package
SPSS 13.0. All experiments were repeated independently,
at least three times. Values are given as means ± SD. The
possible correlation between methylation status and clin-
icopathological features were analysis using Pearson Chi-
Square test. RASSF1A expression level in NPC primary
tumors compared to normal nasopharyngeal epithelia
and RASSF1A-methylated tumors compared to unmethyl-
ated tumors were analysis by using Mann-Whitney's U
test. P < 0.05 was considered to be statistically significant.
Results
Expression of RASSF1A in NPC cell lines and 
nasopharyngeal biopsy specimen
The two NPC cell lines had a low expression level of
RASSF1A and all of the normal nasopharyngeal epithelial
biopsies expressed an easily detectable level of RASSF1A.
The overall expression of RASSF1A in 38 primary NPC
tumors was down-regulated compared to that of 14 nor-
mal nasopharyngeal epithelial biopsies (p < 0.01), and
with completely silenced of RASSF1A expression in 2 cases
of primary NPC tumors (Figure 1).
Hypermethylation of RASSF1A in NPC cell lines, primary 
tumorsand normal nasopharyngeal epithelia
Promoter hypermethylation of RASSF1A could be
detected in 71.05% (27/38) of the primary NPC tumors
but not in the normal NP epithelia (Figure 2a). MSP anal-
ysis of RASSF1A promoter in NPC cell lines, CNE-1, CNE-
2 is shown in Figure 2b. DNAs from the two cell lines
could be amplified with both methylated and unmethyl-
ated DNA-specific primers. This result revealed that these
two cell lines were partial methylation.
Inactivation of RASSF1A correlates with its 
hypermethylation
Based on the RT-PCR result and MSP analysis, methyla-
tion of RASSF1A could be detected in 2 NPC cell lines in
which RASSF1A expression were down-regulated. The
normal nasopharyngeal epithelial biopsies, which have a
normal expression level of RASSF1A, presented only
unmethylated alleles. Additionally, a decreased level of
RASSF1A expression could be detect in RASSF1A-methyl-
ated 27 primary NPC cases compared to unmethylated
NPC cases (p < 0.05, Figure 3b).
To further demonstrate that promoter hypermethylation
contributes to the lack of expression of RASSF1A in the
NPC cell lines, we assessed the effect of 5-aza-2'-deoxycy-
tidine, a drug that inhibits DNA methylation. CNE-2 had
lower expression of RASSF1A than CNE-1 had in our stud-
ies. So CNE-2 was chosen and treated with 0, 1, 3, 5, 7, or
10 μmol/L of 5-aza-dC for 4 d. We observed that the re-
expression level of RASSF1A was gradually up-regulated
alone with the increase of drug concentration (Figure 3a),
but little change could be observed in the expression of
the internal control gene GAPDH. Then the methylation
status of RASSF1A in each concentration groups showed
that the groups of 0, 1, 3, 5 μmol/L showed amplification
for both methylated and unmethylated sequences, but in
the groups of 7 and 10 μmol/L of 5-aza-dC treatment,
only unmethylated alleles could be detected (Figure 3c).
Clinicopathological significance of RASSF1A promoter 
hypermethylation
A significant correlation was observed between the fre-
quency of promoter hypermethylation of RASSF1A and
the differentiation degree of the tumor (χ2 = 4.932, p <
0.05), but no correlation was observed between promoter
methylation of RASSF1A and the patients' age, gender,
clinical stage, lymph node metastasis or distance metasta-
sis (p > 0.05) (Table 1).
(a) Expression level of RASSF1A in NPC cell lines, normal  nasopharyngeal epithelial and primary tumor biopsies by RT- PCR, T, primary nasopharyngeal tumor tissues; N, normal  nasopharyngeal epithelial; M; marker I Figure 1
(a) Expression level of RASSF1A in NPC cell lines, 
normal nasopharyngeal epithelial and primary tumor 
biopsies by RT-PCR, T, primary nasopharyngeal 
tumor tissues; N, normal nasopharyngeal epithelial; 
M; marker I. GAPDH was amplified as an internal control. 
(b) Summary of overall expression of RASSF1A in 38 pri-
mary NPC tumors and 14 normal nasopharyngeal epithelial 
biopsies. RASSF1A expression was significantly down-regu-
lated in NPC primary tumors compared with normal 
nasopharyngeal epithelial (p < 0.01, Mann-Whitney's U test).Journal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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Exogenous expression of RASSF1A and K-Ras 
synergistically inhibits cell growth
To determine the growth inhibition effect of RASSF1A,
CNE-2 cells were transfected with RASSF1A ± activated K-
Ras, the transfect efficiency was measured by RT-PCR and
western-blot analysis respectively (Figure 4a). After exam-
ined for 48 h, modest growth inhibition was detected with
RASSF1A alone, but this effect was dramatically enhanced
by the presence of activated K-Ras (Figure 4b). We
observed that RASSF1A on its own promoted modest cell
death as the amount of blue dead cells were less. But in the
presence of activated K-Ras12V, the dead blue cells were
enhanced greatly (p < 0.01, Figure 5). It seems that co-
transfection of these two genes together could induced
synergistic cell death effect.
RASSF1A mediate cell cycle arrest and Ras-dependent 
apoptosis
48 h post-transfection, analysis of propidium iodide
incorporation of the RASSF1A-expression CNE-2 cells
showed an 11% increase in G0/G1 phase cell population
than that of empty vector expression CNE-2 cells (p  <
0.01) (Figure 6).
What's more, compared to the empty vector, RASSF1A on
its own could promote apoptosis, but activated
Ras(G12V) dramatically stimulated this apoptosis effect
(p  < 0.001)(Figure 7). Thus, based on this result, we
believed that ectopic expression of RASSF1A could inhibit
tumorigenicity through induction of cell cycle arrest in
G0/G1 phase, and mediated apoptosis in a Ras-dependent
manner.
Discussion
Recent studies concerned with epigenetic research are
mostly focus on the RASSF1 family, which has three major
transcripts, A, B and C. The transcript A and C were
expressed in all normal tissues, but RASSF1A expression
was impaired in a number of lung tumor cell lines and in
several other cancer cell lines [10,11]. Loss of expression
was correlated with methylation of the CpG-island pro-
moter sequence of RASSF1A. Reintroduction of RASSF1A
in SCLC lines reduces colony formation, suppressed
anchorage-independent growth and inhibited tumor for-
mation in nude mice[18]. Moreover, it was reported that
Rassf1a-knockout mice are apt to suffer from various can-
cers[23]. These characteristics lead to a proposal that the
RASSF1A isoform is the major tumor suppressor gene
(a) Methylation-specific PCR analysis of RASSF1A promoter  region in NPC primary tumors and normal nasopharyngeal  tissues Figure 2
(a) Methylation-specific PCR analysis of RASSF1A 
promoter region in NPC primary tumors and normal 
nasopharyngeal tissues. Three NPCs (T12, T22, T25) and 
two normal nasopharyngeal (N12, N10) were showed as 
examples. DNA modified by methylase SssI severed as a pos-
itive methylation control and water was included as blank 
control. M: methylated alleles; U: unmethylated alleles. (b) 
Methylation status of RASSF1A in NPC cell lines CNE-1 and 
CNE-2, DNAs from these two cell lines could be amplified 
with both methylated (M) and unmethylated (U) DNA-spe-
cific primers.
(a) Re-expression of RASSF1A by treatment with 5-aza-2'- deoxycytidine in CNE-2 cell lines at different concentration  (0, 1, 3, 5, 7, 10 μmol/L), and GAPDH was amplified as an  internal control Figure 3
(a) Re-expression of RASSF1A by treatment with 5-
aza-2'-deoxycytidine in CNE-2 cell lines at different 
concentration (0, 1, 3, 5, 7, 10 μmol/L), and GAPDH 
was amplified as an internal control. (b) Summary of 
RASSF1A expression in RASSF1A-methylated and--unmethyl-
ated NPC primary tumors. Inactivation of RASSF1A expres-
sion was significantly correlated with promoter 
hypermethylation of RASSF1A (p < 0.05, Mann-Whitney's U 
test). (c) The methylation status of RASSF1A after the treat-
ment of 0, 1, 3, 5, 7, 10 μmol/L of 5-aza-2'-deoxycytidine in 
CNE-2 cells.Journal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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inactivated in many kinds of tumors by promoter methyl-
ation, which is the major mechanism for inactivation of
RASSF1A since an observation of point mutation in
RASSF1A gene was found to be a rare event in a majority
of human cancers[24]. Chow et al. and Steinmann et al.
demonstrated that RASSF1A is a critical tumor suppressor
gene harboring with high frequency of promoter methyl-
ation, which is located on 3p21.3 in NPC[13,25].
In our study, we detected that RASSF1A mRNA expression
was down-regulated in NPC cell lines and primary
tumors. Methylation specific PCR and RT-PCR analysis
also revealed a correlation between RASSF1A expression
level and methylation status in NPC cell lines, primary
tumors and normal epithelial. 5-aza-2'-deoxycytidine
treatment further confirmed that promoter hypermethyl-
ation contributes to the lack of expression of RASSF1A in
the NPC cell lines. Base on these findings, hypermethyl-
ated DNA could be served as a potential molecular tumor
marker that distinguishes cancers from normal tissues.
Our MSP analysis showed that RASSF1A methylation was
frequent in NPC, as the RASSF1A promoter region was
subjected to methylation in 71.05% of the primary
tumors, the two NPC cell lines that we examined were also
both partial methylation. In addition, our findings of a
lack of RASSF1A methylation in the normal nasopharyn-
geal epithelia support the fact that epigenetic silencing of
RASSF1A is a tumor specific process. Moreover, hyper-
methylation of RASSF1A can be detected in both early-
stage and advanced NPC tumors, suggesting that RASSF1A
gene promoter methylation might play an important role
in the early development of nasopharyngeal carcinogene-
sis.
Although the fact that a high frequency of promoter
hypermethylation of RASSF1A that function as a tumor
suppressor is widely accepted by many researchers, and
the growth inhibition effect of RASSF1A in CNE-2 cells
was observed by trypan blue dye exclusion assays in our
present studies. However, the regulation and mechanism
of action of RASSF1A remain a topic of intense investiga-
tion [26]. It appears that like many other critical tumor
suppressors, RASSF1A is multifunctional, thus, inactiva-
tion of RASSF1A may impact many different facets of
tumor biology. In vitro expression of RASSF1A in H1299
lung carcinoma cells inhibited cell cycle progression by
negatively regulating the accumulation of cyclin D1
through a posttranscriptional mechanism [27]. It was
reported that RASSF1A overexpression in gastric carci-
noma cell lines led to a cell cycle arrest at G1 phase, and
activator protein-1(AP-1) is necessary for this process[28].
A recent research indicated that SKP-2, an oncogenic sub-
unit of an ubiquitin ligase complex, which founctions as
a critical regulator of S phase progression, could promote
degradation of RASSF1A at the G1/S checkpoint and then
lead to the cell cycle proceeding in hepatocellular carci-
noma[29]. In our study, we further confirmed the ability
of RASSF1A to induce cell cycle arrest in NPC cell line
CNE-2. Furthermore, RASSF1A was found to be capable of
inducing apoptosis in our result although it was not
observed by some other study[27]. Previous studies indi-
cated that there are several different apoptotic pathways
that RASSF1A is said to be involved in. It was observed by
Table 1: Correlation between RASSF1A promoter methylation and clinicopathological index in NPC
No. of patient Promoter methylation status Frequency of methylationincidence
Methylated Unmethylated
Gender NS
Male 22 17 5 77.27%
Female 16 10 6 62.50%
Age NS
≤50 17 14 3 82.35%
>50 21 13 8 61.90%
Histological subtype p = 0.047
poorly differentiated 27 22 5 81.48%
Well-differentiated 11 5 6 45.45%
Stage NS
I and II 13 9 4 69.23%
III and IV 25 18 7 72.00%
Lymph node NS
Positive 29 22 7 75.86%
Negative 9 5 4 55.56%
Distance metastasis NS
Positive 5 4 1 80.00%
Negative 33 23 10 69.70%Journal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
Page 7 of 11
(page number not for citation purposes)
Vos et al. that RASSF1A can activate Bax via MOAP-1(a Bax
binding protein) and activated K-Ras, thus, RASSF1A and
MOAP-1 synergize to induce Bax activation and cell
death[17]. Also, RASSF1A was found to invovled in death
receptor-dependent apoptosis through MOAP-1. Upon
tumor necrosis factor α (TNF-α) stimulation, MOAP-1
associates with the TNF receptor 1, subsequently,
RASSF1A was recruited to this complex and then partici-
pates in the death receptor-dependent apoptosis[30].
The Ras-signaling pathway also plays an important role in
tumorigenesis. Although Ras oncoproteins were initially
characterized as suppressor of apoptosis, it is now clear
that they also have the ability to promote apoptosis and
inhibit proliferation, that serve as a protective mecha-
nism[19]. The Ras family proteins are a group of mem-
brane-bound small GTPase which comprise 21 members
such as H-Ras, K-Ras and N-Ras. As a negative effector of
Ras, RASSF1A may shift the balance of Ras signaling path-
way toward a cell growth inhibition including senescence,
apoptosis and cell cycle arrest. Several studies have con-
firmed the ablilty of RASSFs family to interact with differ-
ent Ras family proteins. RASSF1A is a pro-apoptosis
protein that has a potential Ras association (RA) domain,
which makes the RASSF1A has the theoretical potential to
bind to Ras directly in vitro, and form a complex with acti-
vated K-Ras when overexpressed in cells[31,32]. This sug-
gests that it may function as an effector for Ras. However,
some authors have failed to see direct binding between
Ras and RASSF1A, they suggest that the interaction is indi-
rect or RASSF1A alone binds only weakly to Ras protein
due to heterodimerization of RASSF1A with NORE1[33].
But RASSF2, another member of RASSFs family, is
thought to possess the ability to bind directly to K-Ras in
a GTP-dependent manner via its RA domain[34]. In our
studies, we have hypothesized that RASSF1A may serve as
an effector that mediate Ras-associated growth inhibition
effect, including Ras-dependent apoptosis. Consequently,
to examine the potential modulation of RASSF1A activity
by Ras, we decided to measure the consequence of acti-
vated K-Ras12V expression on RASSF1A-induced growth
arrest of human nasopharyngeal carcinoma cell lines. The
expression of mutated K-Ras which is an activated form of
this gene is rare in nasopharyngeal carcinoma but is com-
mon in some other tumor types, with as high as 90% in
pancreatic carcinomas, 30% in NSCLC [35]. As we could
observed, RASSF1A has an endogenous ability to promote
apoptosis in CNE-2 cells, however, this activity is indeed
dramatically stimulated by activated K-Ras in nasopha-
RASSF1A-mediated growth inhibition and cell death is  enhanced by K-RasG12V Figure 4
RASSF1A-mediated growth inhibition and cell death 
is enhanced by K-RasG12V. CNE-2 cells were transiently 
transfected with RASSF1A ± activated K-Ras. Trypan blue 
was added in situ after 48 h, and the dye uptake was quanti-
tated. (a) Transfect efficiency of RASSF1A and K-RasG12V is 
confirmed by RT-PCR and western-blot. B: blank group, V: 
empty vector group, E: experimental group;(b) Cell death 
assays; up-panel: CNE-2 cells were transfected with 
RASSF1A ± K-RasG12V, phase contrast microscopic digital 
images were taken at 48 h post-transfection, RASSF1A pro-
moted a modest growth inhibition that was enhanced by the 
presence of activated K-RasG12V; lower-panel: Trypan blue 
in situ staining, the dye uptake was enhanced when RASSF1A 
was co-expressed with activated K-Ras.
Quantification analysis of the result of cell death assay is the  average of three experiments Figure 5
Quantification analysis of the result of cell death 
assay is the average of three experiments. *: vs Vector 
group, p < 0.001; (Black triangle): vs RASSF1A group, p < 
0.01.Journal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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ryngeal carcinoma cell lines CNE-2, which is contrast to
the observations by Shivakumar et al in mammary adeno-
carcinoma cells[27]. Although we were unable to explore
the concrete association mechanism between RASSF1A
and activated Ras, synergistic effect of the co-expression of
the two genes could be confirmed by cell death assays and
apoptosis analysis. These data leading to the possibility
that Ras may positively regulate the activity of endog-
enous RASSF1A. In addition, a mutual exclusion between
RASSF1A inactivation by methylation and K-Ras mutation
was observed in a number of human cancers such as pan-
creatic cancer and endometrial carcinoma[36,37], sup-
porting the association of RASSF1A with the Ras signaling
pathways.
Nasopharyngeal carcinoma is a radiosensitive cancer. The
early-diagnosed patients who receive the treatment of
radiotherapy with or without chemotherapy would acc-
quire a high curative rate. A reliable molecular marker
need to be identified to diagnose and predict the progres-
sion and prognosis of NPC. It was reported by Chang et al.
that a high detection rate of tumor surpressor genes such
as RASSF1A could be evaluated in peripheral blood,
mouth and throat rinsing fluid and nasopharyngeal swabs
of NPC patients, indicating the potential role of epigenetic
events in non-invasive screening of NPC[38]. Moreover,
inactivation of RASSF1A was found to be correlated with
lymph node metastasis[39] and tumor stage in NPC[8],
however, it was not observed in our group. These investi-
gations support the possibility of methylation of tumor
suppressor genes could be a sensitive marker in diagnos-
ing and predicting nasopharyngeal carcinogenesis.
Although hypermethylation of the promoter sequence is
the major mechanism that leads to inactivation of tumor
suppressor genes, fortunately, this modified process could
be reversed as there is no alterations on the gene
sequences, employment of the demethylated agent 5-aza-
2'-deoxycytidine could induce the recovery of the function
of these tumor suppressor gene [18] and it indeed hap-
pened in NPC. This suggests that alteration of the epige-
netic changes of the gene would be a new way of tumor
therapy.
Ectopic expression of RASSF1A induces cell cycle arrest Figure 6
Ectopic expression of RASSF1A induces cell cycle arrest. (a) Cell cycle arrest effect of RASSF1A, the CNE-2 cells 
were transiently transfected with either empty vectors or RASSF1A-expression vectors, after 48 h, the CNE2-RASSF1A cells 
showed a 11% increase in G0/G1 phrase cells than CNE2-empty vector cells. (b) The statistical analysis of the cell cycle distri-
bution. *: vs Vector group, p < 0.01.Journal of Experimental & Clinical Cancer Research 2009, 28:160 http://www.jeccr.com/content/28/1/160
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Conclusion
In summary, the expression of RASSF1A was markedly
reduced or completely lost in primary nasopharyngeal
carcinoma compared with normal nasopharyngeal epi-
thelia, and was correlated to hypermethylation of the pro-
moter of the RASSF1A gene. The tumor suppressor
function of this gene involved in cell cycle arrest, inhibit-
ing cell proliferation and inducing apoptosis. Further-
more, our study confirmed that these growth-inhibitory
properties could be enhanced by activated K-Ras,
although the physiological interaction between Ras and
RASSF1A has yet to be elucidated. Further studies are
needed to be focused on understanding the molecular
mechanism of RASSF1A activity. In a word, RASSF1A rep-
resents an important potential diagnostic and therapeutic
target and the loss or inactivation of RASSF1A may be a
critical component of the evolution of Ras-dependent
tumors.
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